Brian is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced advisor to biopharmaceutical companies.
Brian joined Frazier in January 2016 and co-founded Hawkeye Therapeutics, a search company focused on in-licensing and developing high-quality assets from pharmaceutical companies. He is currently Chief Business Officer at Frazier portfolio company Cirius Therapeutics, which is developing the next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH).
Previously, Brian served as Vice President of Corporate Development and Operations at Sequel Pharmaceuticals, a company focused on the development of a treatment for arrhythmia. Prior to Sequel, he was responsible for corporate development at NovaCardia through its acquisition by Merck in 2007. Before this, he was a global marketing associate at Eli Lilly on the Cialis product team with responsibility for product launch and new indications, and worked in marketing and sales operations for Prudential HealthCare and in public health program management.
Brian earned his M.B.A. from the University of Texas and a B.S. from Trinity University.
University of Texas (M.B.A.)
Trinity University (B.S.)